Latest news with #ScottSchoenhaus
Yahoo
16-06-2025
- Business
- Yahoo
Hinge Health: Why this analyst is bullish on the stock
Wall Street analysts began to initiate coverage of Hinge Health (HNGE), which went public back on May 22. One of the analysts making a call on the stock was KeyBanc Capital Markets equity research analyst Scott Schoenhaus, who gave it an Overweight rating. He explains why in the video above. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here. So, Hinge is an app-based platform. The provider, the therapist, is the app themselves. Very much different from, like, a third party, like Teledoc, that was supposed to be an intermediary. So yes, you're correct in comparing it to that the the device itself is the provider. How it's differentiated from a Mirror, for example, is that you actually have real physical therapists guiding you, and there's an AI technology that is measuring a hundred points on your body and actively telling you and encouraging how to do the certain exercises or sessions in a very advanced technology. And then they also send out these devices that help you that stimulate your nerves to help you ease the pain if you're in really chronic pain and can't complete exercises. So, I would say it's a little more technologically advanced, the providers actually a physical therapist, they're leveraging more and more AI to, you know, have leverage these physical therapists or care team members to an actual member, and that's led to, you know, really strong gross margins above 80%. Um, so it's a really, really, um, you know, technology first platform. Who would you consider their competitors, Scott? And what is their competitive advantage? Yeah, the two main competitors are really Sword and Kaia. Um, they're offering sort of digital MSK solutions. MSK? Musculoskeletal? Musculoskeletal, yes. So anything to do with your muscles, skeletons, joints, which is the largest spending in healthcare for America outspends diabetes and cardiovascular. So huge market. But those solutions, for example, send you a tablet. It's not on your phone. They don't have the technology, the 3D technology like we talked about to measure the hundred points on your body. They don't have these Enzo devices. They are not in network with all these health plans in the way that Hinge has done over the last several years, which I think is a really strong competitive moat, that these health plans actually want to use the platform. So they're really seeing, you know, hard dollar ROI. This is something we highlighted in our report this morning. You know, just looking at PT, in-person PT, not even going down the route of back surgeries, which could be very expensive. A PT session is usually $120 per session. You're usually supposed to go two times a week over eight weeks. That can get to almost $2,000. The Hinge cost to your employer is somewhere between $900 and $1,000 per year. Well, I was going to say, though, I mean, when you talk about competition, isn't the biggest competition going to a physical therapist, right? I mean, so how do does something like Hinge Health convince more people to, because as you say, part of it, I guess, is is convincing the employee health employer health plan. There, from a cost perspective, it's probably an easy sell. But if I'm an individual, and I want that, you know, in in person effect, that might be tougher. Yeah. So as someone who actually had has had physical therapy, in-person physical therapy, um I know the struggle of initiating getting someone that's in your network. And then if you have a high deductible plan, you are paying that deductible right at the, you know, your first several appointments could be thousands of dollars. Um, Hinge is really a user-friendly, no cost to the actual user, the employee. Your employer pays all the cost. It's they send you um a, you know, all the technology equipment that you need to like put your phone up, a mat, they send you this Enzo device that we talked about. Um, so they are trying to get people engaged on the platform in a very user-friendly and seamless way that avoids all the, you know, the the pains of going to an in-person physical therapist. You have to take off time. I mean, it's it can be a cumbersome process just to even find a physical therapist that's in your network that will be covered by your insurance provider.
Yahoo
16-06-2025
- Business
- Yahoo
Hinge Health: Why this analyst is bullish on the stock
Wall Street analysts began to initiate coverage of Hinge Health (HNGE), which went public back on May 22. One of the analysts making a call on the stock was KeyBanc Capital Markets equity research analyst Scott Schoenhaus, who gave it an Overweight rating. He explains why in the video above. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-05-2025
- Business
- Yahoo
Why Doximity (DOCS) Shares Are Trading Lower Today
Shares of healthcare professional network Doximity (NYSE:DOCS) fell 11.7% in the afternoon session after the company reported weak first quarter 2025 results: its revenue guidance for next year fell short of Wall Street's estimates and suggested a significant slowdown in demand. Notably, top-line growth decelerated significantly, up 17% (versus 25% growth in the previous quarter). On the other hand, Doximity blew past analysts' revenue and EBITDA expectations this quarter. Overall, this was a weaker quarter. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Doximity? Access our full analysis report here, it's free. Doximity's shares are very volatile and have had 24 moves greater than 5% over the last year. But moves this big are rare even for Doximity and indicate this news significantly impacted the market's perception of the business. The biggest move we wrote about over the last year was 6 months ago when the stock gained 48.2% on the news that the company reported impressive third-quarter earnings, which blew past analysts' revenue, EPS, and EBITDA expectations. Sales improved significantly, driven by robust platform engagement, particularly in new products like AI-powered workflow tools and the expanded client portal. The improved engagement facilitated upselling among top pharma clients. The company recorded an impressive 56% adjusted EBITDA margin, highlighting disciplined cost management, which was supported by higher incremental margins from digital products. The business observed stabilization in key markets, including strong growth in pharma budgets and increased adoption of digital solutions. Guidance was also strong as the company lifted its full-year sales outlook, while the EBITDA forecast came in ahead of consensus. Zooming out, we think this was a strong quarter for the company. Following the result, Keybanc analyst Scott Schoenhaus upgraded the stock's rating from Neutral to Buy on hopes for momentum to improve heading into the last quarter of the year. Doximity is down 2.4% since the beginning of the year, and at $52.25 per share, it is trading 37.2% below its 52-week high of $83.14 from February 2025. Investors who bought $1,000 worth of Doximity's shares at the IPO in June 2021 would now be looking at an investment worth $985.99. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
Yahoo
16-05-2025
- Business
- Yahoo
Why Doximity (DOCS) Shares Are Trading Lower Today
Shares of healthcare professional network Doximity (NYSE:DOCS) fell 11.7% in the afternoon session after the company reported weak first quarter 2025 results: its revenue guidance for next year fell short of Wall Street's estimates and suggested a significant slowdown in demand. Notably, top-line growth decelerated significantly, up 17% (versus 25% growth in the previous quarter). On the other hand, Doximity blew past analysts' revenue and EBITDA expectations this quarter. Overall, this was a weaker quarter. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Doximity? Access our full analysis report here, it's free. Doximity's shares are very volatile and have had 24 moves greater than 5% over the last year. But moves this big are rare even for Doximity and indicate this news significantly impacted the market's perception of the business. The biggest move we wrote about over the last year was 6 months ago when the stock gained 48.2% on the news that the company reported impressive third-quarter earnings, which blew past analysts' revenue, EPS, and EBITDA expectations. Sales improved significantly, driven by robust platform engagement, particularly in new products like AI-powered workflow tools and the expanded client portal. The improved engagement facilitated upselling among top pharma clients. The company recorded an impressive 56% adjusted EBITDA margin, highlighting disciplined cost management, which was supported by higher incremental margins from digital products. The business observed stabilization in key markets, including strong growth in pharma budgets and increased adoption of digital solutions. Guidance was also strong as the company lifted its full-year sales outlook, while the EBITDA forecast came in ahead of consensus. Zooming out, we think this was a strong quarter for the company. Following the result, Keybanc analyst Scott Schoenhaus upgraded the stock's rating from Neutral to Buy on hopes for momentum to improve heading into the last quarter of the year. Doximity is down 2.4% since the beginning of the year, and at $52.25 per share, it is trading 37.2% below its 52-week high of $83.14 from February 2025. Investors who bought $1,000 worth of Doximity's shares at the IPO in June 2021 would now be looking at an investment worth $985.99. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
